Alpha 2.0
Login Register
» Authors » Gunter Derigs

Gunter Derigs

Explore the profile of Gunter Derigs including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 73
Followers 0
Related Specialties
Hematology
General Surgery
Oncology
Top 10 Co-Authors
Hannes Wandt
Jochen Casper
Axel Zander
Hermann Einsele
Andreas Krull
Nicolaus Kroger
Thomas Gauler
Georg Hess
Bernd Metzner
Arthur Gerl
Published In
Haematologica
Bone Marrow Transplant
Biol Blood Marrow Transplant
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation
Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, et al.
Haematologica . 2013 Jan; 98(5):765-70. PMID: 23300179
High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study,...
2.
Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma
Kroger N, Einsele H, Derigs G, Wandt H, Krull A, Zander A
Biol Blood Marrow Transplant . 2010 Feb; 16(6):861-4. PMID: 20139025
We report long-term results after a median follow-up of 105 months in 18 patients with multiple myeloma who received an intensified myeloablative conditioning regimen regimen consisting of modified total body...
3.
Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group
Hartmann J, Gauler T, Metzner B, Gerl A, Casper J, Rick O, et al.
J Clin Oncol . 2007 Dec; 25(36):5742-7. PMID: 18089869
Purpose: To evaluate the feasibility and the toxicity of sequential, dose-intensified chemotherapy combined with paclitaxel plus peripheral blood-derived hematopoietic stem-cell support (PBSC) for patients with untreated metastatic germ cell tumors...
4.
Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study
Bourhis J, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, et al.
Haematologica . 2007 Jul; 92(8):1083-90. PMID: 17640853
Background And Objectives: This European Group for Blood and Marrow Transplantation (EBMT) multicentre randomized phase III study was designed to assess the safety and efficacy of CD34+ selection in newly...
5.
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)
Kroger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, et al.
Bone Marrow Transplant . 2003 May; 31(11):973-9. PMID: 12774047
We investigated toxicity and efficacy of in vivo T-cell depletion with anti-thymocyte globulin (ATG) as part of an intensified myeloablative conditioning regimen followed by allogeneic stem cell transplantation in patients...